Patiromer

Summary

Patiromer (CHEMBL2107875) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including chronic kidney disease and heart failure.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 20

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107875
Name	Patiromer
Type	Small molecule
Max phase	3

Also known as: Patiromer, PATIROMER

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic kidney disease	3	MONDO:0005300	EFO:0003884
heart failure	2	MONDO:0005252	EFO:0003144

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE2	9
PHASE4	7
PHASE3	3
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02694744	PHASE4	COMPLETED	Patiromer With or Without Food for the Treatment of Hyperkalemia
NCT02933450	PHASE4	COMPLETED	Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
NCT03183778	PHASE4	COMPLETED	Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.
NCT03229265	PHASE4	COMPLETED	Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer
NCT04142788	PHASE4	TERMINATED	RELieving Increasing oEdema Due to Heart Failure
NCT04585542	PHASE4	TERMINATED	Comparison of Potassium Binders in the ER
NCT05029310	PHASE4	COMPLETED	Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients
NCT01810939	PHASE3	COMPLETED	A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
NCT03740048	PHASE3	COMPLETED	A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease
NCT03888066	PHASE3	COMPLETED	Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
NCT05766839	PHASE2	RECRUITING	Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
NCT00868439	PHASE2	COMPLETED	Evaluation of Patiromer in Heart Failure Patients
NCT01130597	PHASE2	COMPLETED	Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease
NCT01371747	PHASE2	COMPLETED	Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
NCT02033317	PHASE2	TERMINATED	An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
NCT03071263	PHASE2	COMPLETED	Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
NCT03087058	PHASE2	TERMINATED	Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia
NCT03326583	PHASE2	COMPLETED	The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
NCT03799926	PHASE2	COMPLETED	Exploratory Study of ZG-801 for the Treatment of Hyperkalemia
NCT02823626	Not specified	COMPLETED	High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).